Mechanism of metastasis suppression by luteolin in breast cancer

Matthew T Cook
Department of Biology, Washburn University, Topeka, KS, USA

Abstract: Metastatic breast cancer is typically an extremely aggressive cancer with poor prognosis. Metastasis requires the orchestration of homeostatic factors and cellular programs, many of which are potential therapeutic targets. Luteolin (2-[3,4-dihydroxyphenyl]-5,7-dihydroxy-4-chromenone), is a naturally occurring flavonoid found in fruits and vegetables that exhibits many anticancer properties. Luteolin obstructs metastasis through both direct and indirect mechanisms. For instance, luteolin may suppress breast cancer invasion by acting as an antiangiogenic therapeutic inhibiting VEGF production and its receptor’s activity. Furthermore, luteolin decreases epithelial–mesenchymal transition markers and metastatic proclivity. Luteolin also acts as an antiproliferative by suppressing receptor tyrosine-kinase activity and apoptosis, both of which could prevent incipient colonization of breast cancer. Many of these antimetastatic characteristics accredited to luteolin are likely functionally related. For instance, the PI3K/Akt pathway, which is impeded by luteolin, has several downstream programs involved in increased proliferation, survival, and metastatic potential in breast cancer. In this review, luteolin’s ability to ameliorate breast cancer is summarized. The paper also offers insight into the molecular mechanisms by which luteolin may suppress breast cancer metastasis.

Keywords: angiogenesis, MMP, NOTCH, β-catenin, RTK, Akt

Introduction

Breast cancer afflicts millions of women worldwide and is the second-leading cause of cancer related death in US women. Early detection, awareness, and treatment options have significantly improved quality of life in breast cancer survivors. Over a century ago, Paget postulated that metastatic cancer is not determined by chance, but instead depends upon coordinated crosstalk between circulating tumor cells (seeds) and organ-specific microenvironments (soil). In agreement with Paget’s hypothesis, metastatic breast cancer tends preferentially to metastasize to the bone, brain, liver, and lungs. Only 5%–10% of all new cancers are diagnosed as metastatic, and the lack of therapeutic options likely explains why 90% of cancer-related deaths are attributed to metastasis and not primary tumor encumbrance. Preventing tumor metastasis is arguably the paramount challenge to curing cancer, as well-defined localized tumors are manageable with current options.

All potential secondary tumors must first invade, disseminate, and subsequently colonize a hostile environment. These biological events are orchestrated through intrinsic and extrinsic homeostatic factors and molecular pathways, of which many may provide clinical opportunities to mitigate the metastatic propensity of breast cancer. Currently, most chemotherapeutic approaches revolve around obstructing established...
and incipient tumors through a combination of surgical resection and adjuvant therapy. These therapies have exceptional outcomes for breast cancer patients with confined primary tumors; however, metastatic cancer, being systemic in nature and resistant to chemotherapeutics, tends to have poorer prognosis.6 This article addresses the aptitude of luteolin (2-[3,4-di-hydroxyphenyl]-5,7-di-hydroxy-4-chromenone), a natural occurring flavonoid found in fruit and vegetables7 (Figure 1), to combat metastatic breast cancer by focusing on research that exemplifies the capacity of luteolin to abrogate metastatic steps involved in invasion, migration, and colonization (Table 1).

Angiogenesis

The invasion–metastasis cascade begins with neovascularization, the transition from epithelial to mesenchymal subtype, and the dissolution of the proteinaceous extracellular matrix and basement membrane.8 The “angiogenic switch” in carcinogenesis increases potent angiogenic factors, such as platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), increasing tumorigenicity.9–11 VEGF plays an instrumental role in tumor-cell survival, proliferation, and migration.9–13 As such, luteolin significantly reduces VEGFA production in MDA-MB-231 triple-negative breast cancer cells, which lack ER, PR, and HER2 (aka HER2/neu).14,15 An antibody blockade against VEGFR-2, a receptor tyrosine kinase (RTK), has produced results similar to that of luteolin;14 however, a causative link was not established. An in vivo study using progestin-driven T47D breast cancer cells showed that luteolin significantly reduced progestin-stimulated blood vessel formation.16 A similar reduction in blood vessel formation by luteolin is seen in prostate cancer xenografts.17 Luteolin has also been reported in two unrelated studies to reduce MDA-MB-231 lung metastasis in nude mice,14,18 which in part may be attributed to reduced blood vessel formation.

One plausible explanation for the reduction in blood-vessel formation is that luteolin suppresses endothelial cell proliferation and migration, a necessity for angiogenesis and nascent tumor growth.12 Interestingly, MDA-MB-231-conditioned media from cells treated with luteolin reduced tube formation and cell migration in human umbilical vein endothelial cells (HUVECs).15 A gastric cancer study reported luteolin reduced VEGF production in both gastric cancer cells and HUVECs, as well as reduced endothelial cell migration and proliferation.19 Furthermore, luteolin prevented cancer-promoting effects when cocultured with HUVECs and gastric cancer cells.19 Prospectively, this reduced migratory potential may be attributed to luteolin’s efficacy to inhibit VEGF-induced PI3K activity by blocking Akt phosphorylation.14,20 In separate studies, luteolin suppressed VEGF and angiotensin II-induced endothelial cell migration through the downregulation of VEGFR-2 phosphorylation21 and the PI3K/Akt pathway.22 Another article regarding endothelial cells showed that luteolin decreased VEGF-induced VEGFR-2 phosphorylation and downstream effectors, such as Akt (Figure 2).17 Pratheeshkumar et al showed that luteolin reduced kinase activity and proinflammatory cytokines in prostate cancer in vitro.17 Taken together, these reports provide a potential relationship between the ability of luteolin to obstruct VEGF-induced angiogenesis and the prospective colonization of metastatic sites. Speculatively, this relationship may be due to luteolin impeding paracrine signaling between tumors and their microenvironment. However, the mechanism of action needs further research to determine the involvement of VEGF and luteolin in suppression of metastatic breast cancer cells.

Membrane degradation

A key step in neovascularization and tumor invasion is the degradation of the basement membrane, which is facilitated by matrix metalloproteinases (MMPs).23,24 In breast cancer, deregulation of MMP expression promotes invasion and metastasis.25 In particular, several studies implicate MMP-2 and MMP-9 in enabling progression through the metastatic cascade, and MMP-9 being a possible prognostic factor for invasive breast cancer.25 An early kinetic analysis characterized luteolin as a potent non-competitive inhibitor of MMP-9.26 Recent evidence reported in MCF7 and MDA-MB-231 cells confirms the ability of luteolin to decrease both MMP-2 and MMP-9 mRNA and protein expression significantly.15 Likewise, treatment of 12-O-tetradecanoylphorbol-13-acetate-treated MCF7 cells with a luteolin derivative mitigated MMP-9 expression and substantially reduced the invasive potential of these breast cancer cells.27 Park et al attributed the reduced invasive potential to the downregulation of the MAPK

![Figure 1 Chemical structure of luteolin.](https://www.dovepress.com/doi.org/10.2147/BCTPP.S200101)
Mechanism of metastasis suppression by luteolin in breast cancer

Pathway resulting in suppression of the proliferative transcription factors AP-1 and NF-κB. MMPs promote cancer progression by cleaving an array of growth-factor precursors, which increases cell proliferation, invasion, and metastasis. The link between luteolin-driven inhibition of MMPs and decreased metastatic potential is also seen in various other models, and thus warrants further investigation into the mechanism of action for luteolin-induced MMP inhibition.

MMP-mediated degradation of the extracellular matrix releases numerous growth factors and signaling molecules that enable tumor expansion. One such factor normally sequestered in the matrix is the ubiquitous hyaluronic acid (HA). HA is degraded by hyaluronidase into various molecular weights, which then potentiates tumor progression and angiogenesis through one of two receptors: CD44 and RHAMM. In breast cancer, the cell-surface proteins’ CD44+/CD24− profile is indicative of cancer stem-cell-like properties and increased metastatic potential. Luteolin has been shown to be a potent inhibitor of hyaluronidase at relatively high concentrations and to prevent progestin-induced increases in breast cancer.

### Table 1 Effect of luteolin on breast cancer at a glance

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Target</th>
<th>Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA-MB-435, MDA-MB-231*</td>
<td>VEGF/VEGFR-2</td>
<td>Decreased VEGF, cell migration, lung-nodule formation</td>
<td>14</td>
</tr>
<tr>
<td>MDA-MB-231, MCF7</td>
<td>Notch1, VEGF, MMP-2, MMP-9</td>
<td>Reduced invasion potential, Notch1, VEGF, and MMPs</td>
<td>15</td>
</tr>
<tr>
<td>T47D, BT-474</td>
<td>VEGF</td>
<td>Suppressed progestin-induced VEGF, blood vessel, stem-like properties, and tumorigenicity</td>
<td>16</td>
</tr>
<tr>
<td>MDA-MB-231, BT549, MCF7</td>
<td>Wnt/β-catenin MMP-9, IL-8, ERK</td>
<td>Decreased β-catenin, Snail, Slug, vimentin, N-cadherin, and lung-tumor nodules</td>
<td>18</td>
</tr>
<tr>
<td>MCF7</td>
<td>AEG-1, MMP-2</td>
<td>Decreased cell migration and AEG-1 and MMP-2 protein levels</td>
<td>29</td>
</tr>
<tr>
<td>MDA-MB-231, SUM-I49</td>
<td>RSK/YB1, Notch4</td>
<td>Inhibited RSK, Notch4, pGSK-3β, and YB-1 activation</td>
<td>39</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>EGFR/MAPK</td>
<td>Decreased Akt, PLK1, cyclin B1, cyclin A, CDK2, Bcl-xL, and EGF-induced pEGFR; increased p21 and Bax</td>
<td>61</td>
</tr>
<tr>
<td>MCF7*</td>
<td>p21, p38, p53, cyclin D1</td>
<td>Induced p21, p38, and p53; reduced cyclin D1</td>
<td>62</td>
</tr>
<tr>
<td>MDA-MB-453</td>
<td>HER2, Akt, S6K</td>
<td>Decreased HER2 and p21, upregulated p27; increased p21, transient suppression of Akt except at highest dose</td>
<td>63</td>
</tr>
<tr>
<td>MDA-MB-453</td>
<td>HER2</td>
<td>Decreased HER2/neu protein expression</td>
<td>74</td>
</tr>
<tr>
<td>MCF7</td>
<td>DRS, Bcl-2</td>
<td>Enhanced DRS and caspase 8/9/3, inactivated PARP, increased Bax, and inhibited Bcl-2</td>
<td>76</td>
</tr>
<tr>
<td>MCF7</td>
<td>EGFR</td>
<td>Suppressed EGF-induced pEGFR, Akt, pErk1/2, pSTAT3</td>
<td>84</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>STAT3</td>
<td>Paclitaxel combined therapy increased apoptosis, inhibited STAT3, increased FAS expression</td>
<td>87</td>
</tr>
<tr>
<td>MCF7</td>
<td>IGFR, Akt, ERα</td>
<td>Decreased IGF-induced pIGFR, Akt, and ERα, but not ERK; silencing ERα mitigated effects.</td>
<td>91</td>
</tr>
<tr>
<td>MCF7</td>
<td>PKL1</td>
<td>E2 combination therapy blocked PKL1 expression</td>
<td>96</td>
</tr>
<tr>
<td>MCF7</td>
<td>Akt</td>
<td>Reduced doxorubicin-induced cytoxicity, increased Akt and Bcl-2 protein expression</td>
<td>98</td>
</tr>
<tr>
<td>MDA-MB-231, HS-578T, MCF7</td>
<td>Akt, p53, FOXO</td>
<td>Increased p53 and cytochrome C, cleaved PARP, nFOXO3a, p21, and p27; inhibited cell migration, pAkt, and cFOXO3a</td>
<td>101</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>p53</td>
<td>Decreased Bcl-2 mRNA expression and increased p53</td>
<td>102</td>
</tr>
<tr>
<td>MDA-MB-231, MCF7</td>
<td>Akt</td>
<td>Increased apoptosis, decreased Akt</td>
<td>105</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>FAS</td>
<td>↓ FAS and cell viability</td>
<td>109</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>nAChR, AKT, ERK, NFκB</td>
<td>Decreased nicotine-induced c9-nAChR, AKT, ERK, and NF-kB-induced c9-nAChR luciferase activity</td>
<td>117</td>
</tr>
<tr>
<td>MDA-MB-231, MCF7</td>
<td>Cyclin E2</td>
<td>Reestablished tamoxifen efficacy; reduced cyclin E2</td>
<td>119</td>
</tr>
<tr>
<td>MCF7*</td>
<td>MRP</td>
<td>GSX pump inhibition</td>
<td>120</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>cMet</td>
<td>Decreased cMet levels</td>
<td>121</td>
</tr>
<tr>
<td>MCF7, SKBR3, MDA-MB-231</td>
<td>AIF, ERK, p38</td>
<td>Increased ERK, p38 protein, and caspase 3; cleaved PARP; decreased AIF nuclear localization</td>
<td>122</td>
</tr>
<tr>
<td>MCF7</td>
<td>Glycolysis</td>
<td>Reversed hypoxia-induced doxorubicin resistance</td>
<td>123</td>
</tr>
</tbody>
</table>

**Note:** *Variant cell line.*
in CD44+ expression and ALDH activity at low doses.16 In a combination treatment, luteolin prevented paclitaxel-induced CD44+ enrichment.19 Along the same lines, luteolin has been reported to reduce CD44+ expression in prostate cancer,40 as well as reduce CD44+ and ALDH activity in oral cancer cells.41 These observations provide evidence suggesting that luteolin may prevent breast cancer cells from transitioning to a more tumorigenic stem-cell-like phenotype, though the exact mechanism is unknown.

**Tumor microenvironment**

The tumor microenvironment is involved in numerous aspects of tumorigenicity.42,43 Cancer cells interact with surrounding fibroblast, stromal, immune, and endothelial cells through paracrine factors that promote angiogenesis, membrane degradation, epithelial–mesenchymal transition (EMT), colonization, and cancer stem-cell upkeep.8,43 Luteolin, a known anti-inflammatory and antioxidant,44 potentially modifies the tumor microenvironment. As described, luteolin decreases VEGF production, MMPs, and endothelial migration, all of which promote tumor progression. In breast cancer, cytokines coordinate communication between cancer cells and the microenvironment.43 Recent evidence showed a luteolin derivative suppressed 12-O-tetradecanoylphorbol-13-acetate-induced IL-8 mRNA expression.27 The authors attributed the reduction in IL-8, a chemokine associated with advanced-stage breast cancer,45 to MAPK inhibition.27 In pancreatic cancer, luteolin has been shown to reverse IL-6-stimulated EMT by inhibiting STAT3 signaling.52 Similarly, luteolin prevents IL-6/STAT3 signaling in oral cancer.41 In a murine model, luteolin suppressed tumor-associated macrophage (TAM) secretion of promigratory chemokine CCL2 (aka MCP1) and attenuate CCL2-induced Lewis lung carcinoma-cell migration.46 In general, TAMs and other tumor-associated

---

**Figure 2** Luteolin inhibition of receptor-mediated tumor progression.

**Notes:** Involvements of luteolin (green) in modifying processes necessary for metastasis. Notch activation results in removal of the intracellular domain of the membrane-bound Notch receptor, creating the NICD. NICD is blocked by luteolin through an undetermined mechanism. Wnt/β-catenin inhibits GSK3 activity upon activation. Luteolin blocks Wnt-induced phosphorylation of GSK3, and thus prevents GSK3 inhibition. Luteolin has been shown to inhibit RTK activities and their downstream effectors (see text for specific RTKs and associated effector responses). Possible outcomes for each receptor pathway are in the corresponding colored boxes. Intracellular proteins color-coded as protein kinases (blue), TCFs (gray), and other proteins (brown). Dashed line represents possible luteolin interaction.

**Abbreviations:** EMT, epithelial–mesenchymal transition; JAK, Janus kinase; Lu, luteolin; NICD, notch intracellular domain; RSK, ribosomal S6 kinase; RTK, receptor tyrosine kinase; TCF, transcription factor.
immune cells promote metastasis through release of growth factors and cytokines, the latter of which may recruit more immune cells, resulting in signal amplification. In light of this research, luteolin’s ability to reduce cytokine secretion from TAMs may contribute to the perturbation of metastasis. However, the nature by which luteolin arbitrates communication between breast cancer cells and the “soil” remains unclear.

**Wnt/β-catenin signaling**
The Wnt/β-catenin pathway plays a crucial role in morphogenesis and EMT. EMT is strongly associated with increased stem-cell-like properties like self-renewal, and is essential for development of breast cancer metastasis. EMT progression requires concomitant activity of various signal-transduction pathways, such as the Wnt/β-catenin pathway.

In the canonical Wnt pathway, an unbound receptor allows for intracellular GSK3β to phosphorylate β-catenin and initiate proteolytic degradation, thereby reducing β-catenin levels. In contrast, when Wnt conjugates with its receptor, GSK3β activity decreases, enabling β-catenin accumulation and its nuclear localization, resulting in increased β-catenin-orchestrated transcriptional activity and gene expression.

Recent evidence has shown that luteolin effectively reduces β-catenin mRNA and protein levels in the triple-negative breast cancer cell lines MDA-MB-231 and BT-549. Lin et al further showed that luteolin was associated with downregulation of the EMT markers Slug, N-cadherin, vimentin, and Snail and upregulation of the epithelial marker E-cadherin, reinforcing luteolin’s antimetastatic potential. Wnt/β-catenin signaling can result in high nuclear Snail expression driving EMT; furthermore, the inverse relationship between Snail and E-cadherin is indicative of poor breast cancer prognosis.

As such, Lin et al suggested that the anti-EMT capacity of luteolin was mediated through β-catenin. They supported this hypothesis in vitro and in vivo with the observation that overexpression of β-catenin rescued the migratory capacity of MDA-MB-231 cells in the presence of luteolin. Of similar note, in colon cancer cells luteolin reduced the expression of the transcriptionally active forms of β-catenin and the phosphorylation of GSK3β (Figure 2). These data suggest that luteolin may act through the Wnt/β-catenin signaling pathway to suppress EMT, a pinnacle step in invasion and metastasis.

**Notch signaling**
In breast cancer, Notch signaling potentiates EMT through a variety of pathways, including Wnt/β-catenin, TGFβ, and the RTKs. Ligand-receptor-bound Notch initiates the cleavage of Notch intracellular domain (NICD) which then relocates to the nucleus, where it complexes with transcriptional activators that regulate Myc, p21, Hey1, and Hes1. Luteolin suppresses Notch1 signaling and its downstream effectors Hes1 and Hey1 in MDA-MB-231 and MCF7 breast cancer cells. These findings are of particular interest, because Hes1 inhibits the tumor-suppressor PTEN and Hey1 promotes EMT genes, so suppressing Hes1 and Hey1 would likely translate to decreased metastatic propensity.

Reipas et al found that in SUM-149 cells enriched for stem-cell-like properties (CD44+/CD24−), luteolin inhibited Notch 4, with associated loss in cell viability and mammosphere formation. In that study, luteolin acted as a novel p90 ribosomal S6 kinase (RSK) inhibitor in breast cancer cells. The RSK family of proteins are highly conserved downstream effectors of the ERK/MAPK signaling pathway, and regulate cell survival, proliferation, and migration. Also in Reipas et al, in MDA-MB-231 cells, RSK inhibition was accompanied by attenuation of the downstream-transcription factor YB-1 and an associated reduction in Notch4 mRNA signaling. siRNA knockdown of YB-1 resulted in a marked decrease in Notch4 and an associated loss in the NICD, implicating possible mediation between YB-1 and Notch4. Interestingly, the authors noted that siRNA knockdown of YB-1 also increased Notch1 mRNA transcripts; however, they did not attribute this effect to luteolin treatment. Taken together, these studies implicate both Notch1 and Notch4 as possible targets by which luteolin could regulate the metastatic potential of breast cancer, which is encouraging, because the inhibition of Notch4 signaling has been shown to abolish breast cancer tumor formation in vivo completely.

The Notch and Wnt/β-catenin pathways crosstalk, specifically through GSK3β. GSK3β-dependent phosphorylation of the NICD effectively inhibits transcriptional activation of Notch target genes in vitro and in vivo. Luteolin attenuates GSK3β inactivation in the Wnt/β-catenin pathway, and because Akt is known to inactivate GSK3β, it is plausible to suspect that luteolin-induced NICD decrease may be the result of Akt inhibition and increased GSK3β activity. The ability of luteolin to suppress NICDs may be through direct interaction, indirectly through RSK/YB-1, or by preventing inactivation of GSK3β (Figure 2). Luteolin’s capacity to mitigate NICD signaling and by extension metastatic potential could correlate with improved quality of life in breast cancer patients.
colonization, cells transition from a quiescent state to a proliferative state under the control of the cell cycle. The cell cycle controls mitotic division and is regulated through cyclin-dependent kinases (CDKs), cyclins, and their inhibitors p21 (p21Cip1) and p27 (p27Kip1). Deregulation of cell-cycle proteins, such as in upregulation of CDKs in normal mammary tissue, can cause breast cancer.

In light of this, luteolin has been shown to cause cell cycle arrest in many different cancers. In MDA-MB-231 cells, luteolin prevented 3H-thymidine DNA incorporation and arrested cells in the cell cycle G2/M phase. Further analysis of cell cycle-dependent regulatory proteins showed that luteolin induced an increase in p21 expression, as well as an associated suppression of S-phase cell-cycle modulators cyclin A and CDK2 and M-phase protein cyclin B1. Intriguingly, luteolin shows a biphasic response, causing an increase in p21 at low doses and a decrease in p21 at higher doses. P21, a major target of the tumor suppressor p53, inhibits CDK2 preventing cell cycle progression and promotes cell survival, though the latter is dependent upon Akt inhibition of p21 nuclear translocation. Cotreatment of luteolin with p21 siRNA mitigates p21-induced survival advantage. The observed increase in p21 is likely due to luteolin-induced Akt inhibition (Figure 3); however, other possibilities include the ability of luteolin indirectly to modulate DNA topoisomerases I and II (essential DNA-repair proteins) and stabilizing p53 or by a loss of negative feedback from CDK2. Either way, luteolin-mediated regulation of p21, CDKs, and cyclins potentiates cell cycle arrest in breast cancer cells. However, more studies are necessary to elucidate the biphasic response of luteolin on p21 and whether or not luteolin induces changes in p21 localization.

**Human epidermal growth-factor receptor 2**

The HER family consists of four membrane-bound transmembrane receptors, and is associated with cell survival, proliferation, and metastasis in breast cancer. Once a ligand binds to a HER receptor other than an orphan receptor, it preferentially dimerizes with HER2 and subsequently

![Figure 3](https://www.dovepress.com/)

**Figure 3** Luteolin-mediated extrinsic and intrinsic apoptosis in breast cancer.

**Notes:** Illustration abridging the involvement of luteolin (green) in purposed apoptotic pathways. Luteolin sensitized the DR, activated caspase 8, and induced caspase 3-mediated apoptosis. Decreased FAS activity directly or indirectly by luteolin leads to apoptosis through an unknown mechanism. Inhibition of Akt or ERK leads to increased activity in the intrinsic apoptosis pathway. Circumstantially, luteolin acts as an antioxidant or drives ROS-mediated apoptosis. Intracellular proteins color-coded as protein kinases (blue), TCFs (gray), and other proteins (brown). Dashed line represents possible luteolin interaction.

**Abbreviations:** DR, death receptor; Lu, luteolin; ROS, reactive oxygen species; TCFs, transcription factors.
activates the downstream effectors PI3K/Akt and mTOR. HER2 overexpression is diagnosed in approximately 20%–25% of all new breast cancer cases, and even though targeted therapy exists, HER2 breast cancers are associated with poorer prognosis. In MDA-MB-453 breast cancer cells, luteolin at low concentrations has increased HER2 protein degradation in two separate reports. Chiang et al reported that luteolin inhibited cell proliferation, upregulated p27, and downregulated p21 at high doses. P27 regulates cell-cycle progression, and low levels of p27 are typically associated with poorer prognosis in breast cancer patients. The beneficial properties of increased cytosolic p27 may depend upon compartmentalization, as Akt inhibits p27 through Akt-mediated nuclear exclusion, preventing p27-induced cell cycle inhibition (Figure 3). Investigation into MDA-MB-453 cells showed that low/high doses of luteolin, respectively, induced transient and complete suppression of Akt and its effector mTOR. Akt resurgency is prevented when low dose luteolin is coadministered with rapamycin, an mTOR inhibitor, suggesting Akt/mTOR involvement. Additional studies have shown that moderate–high doses of luteolin resulted in decreased cyclin D1 (a principal regulator of G1/S cell cycle transition) and increased p27 accumulation.

In general, HER2-driven tumors are considered “onco-gene-addicted”, meaning that without the oncogene, they cannot survive. Unfortunately, targeting these addicted cancers with TK inhibitors (TKIs) has proven only moderately successful, due to the HER2-driven cancers developing resistance. Recent evidence has shown that the transient effect of TKIs may be due to Akt-mediated negative feedback resulting in HER3 recruitment and thus PI3K/Akt signal restoration. A report using trastuzumab, a HER2 antibody, blockade resulted in suppressed Akt and cyclin D1 activity, with a corresponding increase in p27 in BT-474 and SKBR3 cells, but not in MDA-MB-361 or MDA-MB-453 breast cancer cells. This suggests that the efficacy of TKIs is contingent on whether HER2 inhibition is followed by PI3K/Akt attenuation, and whether or not the TKI can sustain Akt inhibition. In combination therapy, luteolin synergistically enhances lapatinib, a HER2 and epidermal growth-factor receptor (EGFR) inhibitor, and inhibits Akt- and ERK-signaling pathways, resulting in decreased cell proliferation. Interestingly, unlike luteolin, the PI3K inhibitor LY294002 causes complete Akt suppression over 24 hours, but only marginally decreases cyclin D1 in MDA-MB-453 cells. These studies suggest that luteolin may arrest cells by suppressing HER2 signaling through the PI3K/Akt and ERK/MAPK pathways, which may prove advantageous in preventing TKI resistance in breast cancer. The ability of luteolin to degrade HER2, reduce Akt activity, and arrest cells will reduce metastatic potential by preventing incipient colonization.

**EGFR**

EGFR (aka HER1) is an HER-family transmembrane RTK that relays signals through the JAK/STAT, PI3K/Akt, and MAPK-signaling pathways that ultimately affect cell proliferation, apoptosis inhibition, angiogenesis, migration, adhesion, and invasion (Figure 2). While EGFR and its ligands are essential for normal mammary development in the presence or absence of the sex hormones estrogen and progesterone, dysregulation of EGFR leads to breast cancer and metastasis. EGFR is frequently expressed in basal-like breast cancer and is associated with brain metastasis, and the inhibition of EGFR and its ligands reduces breast cancer metastatic potential. Low doses of luteolin inhibit EGFR signaling in a dose-dependent manner by downregulating EGF-induced EGFR phosphorylation and subsequently decreasing the activation of the downstream kinases Akt, ERK, and p38 in MDA-MB-231 breast cancer cells. Similar findings have been reported in MCF7 cells in which moderate doses of luteolin abolished EGF-induced increased pEGFR, Akt, and ERK kinase activity, as well as the transcription factor STAT3. Increasing RTK activity, such as EGFR and HER2, leads to STAT3-induced tumor progression and metastasis. In combination therapy, luteolin and paclitaxel (a cytoskeletal drug) work together to increase expression of the death receptor Fas and reduce STAT3 activation, which results in increased apoptosis in MDA-MB-231 cells (Figure 3). These reports provide a multifaceted approach in which luteolin may reduce breast cancer invasion, metastasis, and colonization by itself or in combination with current chemotherapeutics through modulation of EGFR, PI3k/Akt, and MAPK activity, as well as JAK/STAT signaling.

**Insulin-like growth-factor 1 receptor**

IGF1R is instrumental in normal mammary development. However, in breast cancer IGF1R intrinsically confers survival properties in and of itself, as well as through other RTKs via crosstalk. Clinical studies utilizing monotherapeutic antibodies for EGFR and HER2 breast cancers have resulted in cancers gaining therapeutic resistance, in part due to IGF1R crosstalk. For example, after gaining resistance to gefitinib (an EGFR inhibitor) in MCF7 breast cancer cells, IGF1R dimerizes with EGFR and rescues downstream kinase activity. In the same cell line, albeit...
not a chemotherapeutically resistant version, luteolin abrogates IGF-induced phosphorylation of IGF1R, and the loss in IGFR activity is accompanied by a decrease in Akt but not ERK activity.91 Considering the ability of luteolin to suppress IGFR1 and EGFR pathways as described, luteolin may be able to combat TKI drug-resistant breast cancer.91 Interestingly, Wang et al went on to implicate the transcription factor ERα as the mechanism of action.91 They showed that silencing ERα ameliorated luteolin inhibition of IGF-induced responses.92 Conventional speaking, estrogen-induced proliferation is determined by the ERα:β ratio, with ERα acting in a proliferative manner and ERβ being a functional antagonist.92,93 In regard to this, luteolin has been shown to bind irreversibly to estrogen elements94 and have antiestrogenic or weak estrogenic effects at a similar dosage to that used to inhibit the aforementioned IGFR1 pathway.95,96 These reports suggest that luteolin may antagonize IGF-induced ERα-mediated proliferation by acting as an ERα-competitive inhibitor, resulting in Akt pathway attenuation.

**Luteolin-mediated apoptosis**

The canonical apoptotic pathways include an intrinsic and extrinsic route (Figure 3). The intrinsic apoptotic pathway is mediated by Bcl-2 family members in response to myriad nonreceptor stimuli that ultimately induce changes in mitochondrial membrane integrity, resulting in apoptosis. Bcl-2 family members control apoptosis through varying amounts of pro- and antiapoptotic Bcl-2 proteins (Bad, Bax, BAK, Bcl-2, Bcl-xl),97 essentially acting like a pan balance in determining cell fate. When cytoplasmic Bad increases, Bcl-2 and Bcl-xl dissociate from Bax and BAK and bind to Bad.97 In doing so, Bax and BAK are free to integrate into the mitochondrial membrane, decreasing its integrity, and initiate mitochondrial-mediated apoptosis via caspase-9 (Figure 3).97 In the extrinsic pathway, activated death receptors (DRs) (Fas, TNFR, TRAIL) signal the formation of the death-inducing signaling complex, which subsequently initiates the caspase cascade through caspase-8 and caspase-10.97

In MCF7 breast cancer cells, luteolin induces apoptosis through both extrinsic and intrinsic pathways. Luteolin increases DR expression,76,87 activates caspase-8, and subsequently increases caspase-3 activity in the extrinsic apoptotic pathway. In the intrinsic path, Park et al showed luteolin increases Bax expression and decreases Bcl-2 expression, which in turn decreases mitochondrial membrane integrity, contributing to increased caspase-3 activity via caspase-9 activation.98 Additionally, in MDA-MB-231 cells, low doses of luteolin significantly increase the Bax:Bcl-xL ratio, favoring apoptosis.61 Somewhat confounding are results concerning a luteolin–doxorubicin combination. Sato et al reported that, low-dose luteolin ameliorated doxorubicin (topoisomerase inhibitor) cytotoxicity in part by decreasing doxorubicin-induced reactive oxygen species (ROS) and increasing Bcl-2 in MCF7 cells.99 Flavonoids, including luteolin, are well known for their antioxidative properties;99 however, moderate concentrations of luteolin have been shown to induce ROS in cancer cells (Figure 3).100 In this case, luteolin is likely acting as an antioxidant, but this maybe a dose-dependent effect.

As previously mentioned, luteolin can modify p53 activity indirectly62,65 or directly,68 and p53 mediates the intrinsic apoptotic pathway by regulating Bcl-2 family proteins, specifically through inhibition of Bcl-2 and Bax integration into the mitochondrial membrane.97 In MCF7 cells, luteolin increased p53 protein levels, which results in the release of the intrinsic apoptosis mediator cytochrome C and PARP activation.101 Additional reports confirm the ability of luteolin to increase p53 and decrease Bcl-2 mRNA in MDA-MB-231 cells.102 This presents a novel avenue for luteolin to reduce metastatic colony formation, especially when considering a significant amount of breast cancer contains wild-type P53.103,104 However, the mechanism by which luteolin stabilizes the tumor-suppressor protein p53 and subsequently causes apoptosis in breast cancer is ambiguous.

**FOXO-dependent apoptosis**

In MCF7 breast cancer cells, luteolin shows a marked suppression in active Akt protein, cell migration, and subsequently an increase in apoptosis.101,105 Observations suggest that luteolin decreases cytosolic FOXO3a levels, while it increases nuclear FOXO3a levels over 48 hours.101 Lin et al hypothesized that the nuclear accumulation of FOXO3a was due to the observed loss in Akt (Figure 2).101 In support, recent evidence suggests that Akt inhibition can promote FOXO3a-dependent apoptosis.106 Unphosphorylated nuclear FOXO3a acts as a transcription factor to orchestrate p21 and p27 transcription, in addition to BIM-dependent apoptosis.107 PI3K/Akt-pathway inhibition would prevent phosphorylation of the tumor suppressor FOXO3a, which causes its nuclear exportation and proteolytic degradation.

**FAS-induced apoptosis**

Repressing fatty-acid synthesis in breast cancer has been shown to induce programmed cell death (Figure 3).108 In MDA-MB-231 cells, luteolin reduces FAS (an instrumental lipogenic enzyme) activity, achieving a nearly 50% reduction in cell viability at relatively low doses.109 In liver cancer
cells, luteolin decreases both SREB-1 and FAS mRNA.\textsuperscript{110} In agreement with the luteolin studies, inhibition of MAPK or PI3K signals in breast cancer cells results in decreased SREB-1 transcription and a corresponding decrease in FAS mRNA and protein.\textsuperscript{111} In vivo targeted inhibition of either FAS or SREB-1 has also been shown to reduce tumor burden substantially.\textsuperscript{112} Taken together, these studies suggest that luteolin suppresses FAS through Akt inhibition.

**Conclusion**

Prevention and treatment of metastatic breast cancer will ultimately lead to increased and sustained quality of life for breast cancer patients. Metastasis requires breast cancer cells to undergo morphological changes, migrate, and then colonize at distant sites. Playing a central role is Akt, and its hyperactivity is involved in increased cancer metastasis.\textsuperscript{113} RTKs regulate Akt activity; however, constitutively active Akt can occur in the absence of RTK signaling by deactivating the tumor suppressor PTEN, a possible TKI-escape mechanism.\textsuperscript{114} The ability of luteolin preferentially to disrupt RTKs and/or the downstream effectors Akt, ERK, and STAT3 activity is seen extensively in breast cancer (Table 1) and others.\textsuperscript{32,115–117} These studies provide compelling evidence that luteolin can palliate RTK-induced invasion, metastasis, and colonization.\textsuperscript{32,116,118} Furthermore, luteolin not only inhibits RTK/Akt activity but it may also reestablish therapeutie potency in breast cancers.\textsuperscript{62,119,120} Of note, most of the mechanistic experiments performed utilizing luteolin have been in the metastatic breast cancer cell lines MDA-MB-231 and MCF7 (Table 1). Further studies utilizing the T47D and SKBR3 cell lines may add to the mechanisms of action by which luteolin suppresses metastatic breast cancer in vivo.

**Disclosure**

The author reports no conflicts of interest in this work.

**References**


Dovepress
Mechanism of metastasis suppression by luteolin in breast cancer


85. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Breast Cancer Res. 2002;62(4):4132–4141.


